Humacyte

Humacyte Operating Expenses

The Total Operating Expenses of Humacyte (HUMA) as of Nov 21, 2026 is 100.47 M USD. In the previous year, Total Operating Expenses was 114.40 M USD — a change of -12.17% (lower).

Operating Expenses

100.47 MUSD

YoY

-12.17%

Last updated:

Total Operating Expenses of Humacyte is 2025 100.47 M USD. Total Operating Expenses of Humacyte was 2024 114.40 M USD. It decreases by -12.17% lower compared to the previous year.

The Humacyte Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
91.88 M USD
Jan 1, 2020
65.94 M USD
Jan 1, 2021
82.37 M USD
Jan 1, 2022
86.14 M USD
Jan 1, 2023
99.94 M USD
Jan 1, 2024
114.40 M USD
Jan 1, 2025
100.47 M USD
The Humacyte Operating Expenses history
YEAROperating ExpensesYoY
100.47 MUSD-12.17%
114.40 MUSD+14.46%
99.94 MUSD+16.02%
86.14 MUSD+4.59%
82.37 MUSD+24.91%
65.94 MUSD-28.23%
91.88 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Total Operating Expenses of Humacyte is 100.47 M USD in 2025.

Total Operating Expenses of Humacyte changed from 114.40 M USD to 100.47 M USD, representing a -12.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Humacyte since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Humacyte historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Humacyte

All Key Metrics — Humacyte